Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China Bilthoven, the Netherlands, 20 July 2021 – Intravacc, a world leader in translational research and development of vaccines for infectious diseases and therapeutics, today announced that the Chinese National Medical Products Administration (NMPA)  formally known as the Chinese FDA, granted Sinovac Biotech…

• Sabin-IPV polio vaccine developed by Intravacc contributes to the eradication of polio
• Sinovac’s Eupolio vaccine (sIPV) receives market authorization from the NMPA in China
• Intravacc’s cell technology also used for the development of Sinovac’s Covid-19 vaccine that was introduced on the market recently and is currently under rolling review by EMA

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme disease vaccine. Publication of this study in the peer reviewed scientific journal Vaccine titled “Vaccination…

• Neisserial OMV based Lyme vaccine elicit high antibody titers in mice
• Two conventional vaccines based on Intravacc's OMV platform and VEO cell platform

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine Bilthoven, the Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive pre-clinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray…

• Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2
• Intranasal vaccine administration has significant advantages over injectables
• OMV technology is a powerful vaccine platform for future pandemics